Evolv Technologies Holdings, Inc.

EVLV

CIK 0001805385 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$39M
↑+32.3% +$9Mvs FY2024 (Q4)
Operating Income
$7M
↑+15.0% +$876Kvs FY2024 (Q4)
Net Income
$6M
Gross Profit
$19M
↑+11.3% +$2Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
58/100
  • Profitability
    0ROIC -28.8% (10% = solid, 20%+ = moat)
  • Liquidity
    37Current Ratio 1.23 (above 1.5 = solid)
  • Leverage
    88D/E 0.24 (under 0.5 = conservative)
  • Efficiency
    24Asset Turnover 0.51x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +32.3% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -20.1% · trend +41.0pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project EVLV's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

8%

Trailing CAGR unavailable; default 8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$1.91
Total enterprise IV
$321M
Diluted shares
0.17B
Terminal PV
$233M (72% of total)
Year-5 FCF
$27M
YearProjected FCFDiscounted PV
+1$20M$18M
+2$22M$18M
+3$24M$18M
+4$25M$17M
+5$27M$17M
Terminal$375M$233M

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
investment in PP&E
Stock-based comp (TTM)
$21M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$304M
everything owned
Total liabilities
$185M
everything owed
Stockholders' equity
$119M
shareholder claim
Net debt
$-21M
Net cash position ($21M)

Recent performance · 24 quarters

Revenue↑+32.3% +$9M
$39M
Net Income↑+94.1% +$29M
$-2M
Free Cash Flow↑+386.0% +$12M
$16M
Operating Margin↑+49.9pts
-20.1%

Drill down